Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide
A Khodakarami, MA Kashani, A Nazer… - Cell Communication and …, 2023 - Springer
Background Targeting influential factors in resistance to chemotherapy is one way to
increase the effectiveness of chemotherapeutics. The nuclear factor erythroid 2-related …
increase the effectiveness of chemotherapeutics. The nuclear factor erythroid 2-related …
Advances in monitoring and prognostication for lymphoma by flow cytometry
AP Singh, EL Courville - Clinics in Laboratory Medicine, 2023 - labmed.theclinics.com
Lymphomas comprise a heterogeneous group of diseases with variable clinical
presentations, pathological features, and prognoses. In lymphoma diagnosis, flow cytometry …
presentations, pathological features, and prognoses. In lymphoma diagnosis, flow cytometry …
[HTML][HTML] Cluster of Differentiation Markers and Human Leukocyte Antigen Expression in Chronic Lymphocytic Leukemia Patients: Correlations and Clinical Relevance
M Tizu, B Calenic, AE Constantinescu… - Current Issues in …, 2024 - mdpi.com
Chronic lymphocytic leukemia (CLL) is a distinct category of lymphoproliferative disorder
characterized by the clonal expansion of mature B cells, followed by their accumulation in …
characterized by the clonal expansion of mature B cells, followed by their accumulation in …
Mechanisms of resistance to anti-CD20 antibodies in lymphoid malignancies
A Bordron, M Morel, C Bagacean - Resistance to Anti-Cd20 Antibodies and …, 2024 - Elsevier
Monoclonal antibodies (mAb) belong to a fast-growing therapeutic class. The pan B-cell
marker CD20 represents one of the most-studied mAb targets. The first mAb to receive …
marker CD20 represents one of the most-studied mAb targets. The first mAb to receive …